Literature DB >> 8581190

Should a mild to moderate ischemic mitral valve regurgitation in patients with poor left ventricular function be repaired or not?

J T Christenson1, F Simonet, A Bloch, J Maurice, V Velebit, M Schmuziger.   

Abstract

In recent years coronary artery bypass grafting (CABG) has been extended to include patients with very low left ventricular ejection fractions (LVEF), also frequently with co-existing mild to moderate mitral valve regurgitation (MR). The question is, should such a MR be corrected simultaneously with a myocardial revascularization or not? Between January 1989 and November 1994, 56 patients with preoperative LVEF < or = 25% and echocardiographic evidence of co-existing MR (Grade I: 41%, II: 46%, III: 13%) underwent primary CABG. None of them had simultaneous mitral valve surgery. Twenty-nine patients (52%) had a pulmonary artery pressure (PAP) > 40 mmHg. The mean preoperative LVEF was 17.9 +/- 4.6 (10-25), mean PAP 44.2 +/- 16.1 mmHg. An average of 4.5 +/- 1.5 grafts/patient were placed and five patients had simultaneous repair of a post-infarction left ventricular aneurysm. The overall mortality was 3.6% (2/56). Transient post-operative low cardiac output syndrome occurred in 16 patients (29%). Twenty-one patients (38%) had no postoperative complications at all. The 54 hospital survivors were followed up over a mean period of 12 months (3-36 months). There was one death (eight months postoperatively) and two graft occlusions, not requiring reoperation. At the end of the follow up echocardiography showed that 50 patients (93%) had no (31 patients) or only a very mild Grade I MR (19 patients). Four patients had Grade II MR, none of them requiring mitral valve surgery. All patients improved their NYHA functional class, from 3.4 +/- 0.8 to 1.9 +/- 0.7 and LVEF from 17.9 +/- 4.6 to 44.2 +/- 7.4 (p < 0.001). Coronary artery bypass grafting is a possible treatment for patients with very low LVEF, provided the patient has a two- or three-vessel disease with significant coronary artery stenosis (> 70%) and angina. Mortality and morbidity are low. Moderate co-existing MR (Grade I-III) seems to normalize after myocardial revascularization and should not be surgically corrected therefore at the primary operation.

Entities:  

Mesh:

Year:  1995        PMID: 8581190

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  14 in total

Review 1.  Trends in the surgical management of ischemic mitral regurgitation.

Authors:  Chad E Hamner; Thoralf M Sundt
Journal:  Curr Cardiol Rep       Date:  2003-03       Impact factor: 2.931

2.  Surgical options for the management of ischemic cardiomyopathy.

Authors:  Robert Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

3.  Surgical treatment of moderate ischemic mitral regurgitation.

Authors:  Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

4.  Late outcomes after isolated coronary artery bypass grafting for ischemic mitral regurgitation.

Authors:  Satsuki Fukushima; Junjiro Kobayashi; Ko Bando; Kazuo Niwaya; Osamu Tagusari; Hiroyuki Nakajima; Soichiro Kitamura
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-07

5.  Should a regurgitant mitral valve be replaced simulataneously with a stenotic aortic valve?

Authors:  J T Christenson; B Jordan; A Bloch; M Schmuziger
Journal:  Tex Heart Inst J       Date:  2000

Review 6.  Review of mitral valve insufficiency: repair or replacement.

Authors:  Athanasios Madesis; Kosmas Tsakiridis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Ioanna Kougioumtzi; George Kesisis; Theodora Tsiouda; Thomas Beleveslis; Alexander Koletas; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 7.  Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry.

Authors:  Subhash Padhye; Deepak Chavan; Shubhangini Pandey; Jyoti Deshpande; K Venkateswara Swamy; Fazlul H Sarkar
Journal:  Mini Rev Med Chem       Date:  2010-05       Impact factor: 3.862

Review 8.  Surgical management of moderate ischemic mitral valve regurgitation: Where do we stand?

Authors:  Khalil Fattouch; Sebastiano Castrovinci; Giacomo Murana; Marco Moscarelli; Giuseppe Speziale
Journal:  World J Cardiol       Date:  2014-11-26

9.  Mitral valve repair is not always needed in patients with functional mitral regurgitation undergoing coronary artery bypass grafting and/or aortic valve replacement.

Authors:  J E Lindeboom; W Jaarsma; J C Kelder; W J Morshuis; C A Visser
Journal:  Neth Heart J       Date:  2005-05       Impact factor: 2.380

10.  Mitral valve surgery simultaneous to coronary revascularization in patients with end-stage ischemic cardiomyopathy.

Authors:  Massimo Bonacchi; Edvin Prifti; Massimo Maiani; Giacomo Frati; Nadia S Nathan; Marzia Leacche
Journal:  Heart Vessels       Date:  2006-01       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.